echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nature Immunology: Weiping Zou's team from the University of Michigan reveals a new mechanism of MDM2-p53 inhibitor tumor immunology

    Nature Immunology: Weiping Zou's team from the University of Michigan reveals a new mechanism of MDM2-p53 inhibitor tumor immunology

    • Last Update: 2021-04-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 26, the internationally renowned journal "Nature Immunology" published an online article "The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity" by Dr.


    APG-115 is a new drug under development under Yasheng Pharmaceutical (6855.


    In order to further explore the mechanism of the MDM2-p53 signaling pathway in T cells, the researchers constructed a mouse model that specifically knocked out MDM2 and p53 in T cells.


    Before the start of this study, it is still unknown whether MDM2-p53 will affect the anti-tumor immune response mediated by CD8+ T cells.


    Dr.


    It is reported that Yasheng Pharmaceutical is currently carrying out a phase II clinical trial of APG-115 combined with pembrolizumab to treat patients with tumors that have developed drug resistance or recurrence after PD-1 inhibitor treatment.


    Original source:

    Original source:

    Zhou, J.


    biodiscover.
    com/news/industry/737875.
    html" target="_blank" rel="noopener">The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.